Showing results (2941-2950 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|September 14, 2011
Willingness to pay for adverse drug event regulatory actionsJacoline Bouvy, Just Weemers, Huub Schellekens, et al.Pharmacoeconomics|February 16, 2012
Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndromePaul L McCormackPharmacoeconomics|March 21, 2012
Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphomaJoshua Pink, Steven Lane, Dyfrig A HughesPharmacoeconomics|December 23, 2011
Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilizationSangeeta Budhia, Yeshi Mikyas, Michael Tang, et al.Pharmacoeconomics|January 31, 2012
Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisalHuiqin Yang, Dawn Craig, David Epstein, et al.Pharmacoeconomics|November 27, 2014
Alteplase for the treatment of acute ischaemic stroke: a NICE single technology appraisal; an evidence review group perspectiveMichael Holmes, Sarah Davis, Emma SimpsonPharmacoeconomics|October 27, 2014
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UKP McEwan, H Bennett, T Ward, et al.Pharmacoeconomics|November 21, 2013
Clinical and economic impact of substituting dexmedetomidine for propofol due to a US drug shortage: examination of coronary artery bypass graft patients at an urban medical centreBrandi N Thoma, Julius Li, Cara M McDaniel, et al.Pharmacoeconomics|November 22, 2014
Value-based reimbursement decisions for orphan drugs: a scoping review and decision frameworkMike Paulden, Tania Stafinski, Devidas Menon, et al.Pharmacoeconomics|August 18, 2000
Economics of the antithymocyte globulins Thymoglobulin and Atgam in the treatment of acute renal transplant rejectionM A Schnitzler, R S Woodward, J A Lowell, et al.Pageof 336